Literature DB >> 29236995

A prospective 5-year follow-up study after limited resection for lung cancer with ground-glass opacity.

Motoyasu Sagawa1,2, Hiroyuki Oizumi1,3, Hiroyuki Suzuki1,4, Hidetaka Uramoto1,5, Katsuo Usuda1,5, Akira Sakurada1,6, Masayuki Chida1,7, Satoshi Shiono1,8, Jiro Abe1,9, Tohru Hasumi1,10, Masami Sato1,11, Nobuyuki Sato1,12, Jotaro Shibuya1,13, Hiroyuki Deguchi1,14, Yoshinori Okada1,6.   

Abstract

OBJECTIVES: The incidence of small-sized pulmonary adenocarcinomas with ground-glass opacity (GGO) has recently increased, with excellent postoperative prognosis. The limited resection of such cancers has been deemed to be acceptable based on retrospective studies. We conducted a prospective multi-institutional study evaluating the validity of limited resection for small-sized pulmonary adenocarcinoma with GGO.
METHODS: The inclusion criteria were 25-80 years of age, no prior treatment, a maximum tumour diameter of 8-20 mm, a GGO ratio of ≥ 80%, clinical T1N0M0, lower 18F-fluorodeoxyglucose accumulation than the mediastinum, resectable by sublobar resection, pulmonary lobectomy tolerable and an intraoperative pathological diagnosis of bronchiloalveolar carcinoma. Wedge resection was preferred, but segmentectomy was permitted. Disease-specific survival and overall survival were analysed.
RESULTS: From November 2006 to April 2012, 73 patients were enrolled from 13 institutions. One patient was ineligible, and the remaining 72 patients were preregistered. The tumours of 3 and 14 patients were intraoperatively diagnosed as benign lesions and adenocarcinomas with mixed subtype, respectively. Intraoperative cytological/histological examination of surgical margin was not performed in 2 patients, and the remaining 53 patients were ultimately eligible for this study. The mean tumour size was 14.0 mm and the mean GGO ratio was 95.9%. Thirty-nine and 14 patients underwent wedge resection and segmentectomy, respectively. Although all tumours were intraoperatively diagnosed as bronchioloalveolar carcinomas, 6 were ultimately diagnosed as adenocarcinoma with a mixed subtype. No completion lobectomy was performed. As of 1 May 2017, no recurrence of the original lung cancer was observed during 60.0-126.3 months after surgery. Two patients died from other diseases. The 5-year disease-specific and overall survival rates were 100% and 98.1%, respectively. The reduction in the pulmonary function after limited resection was minimal.
CONCLUSIONS: With these criteria, limited resection was performed safely without any recurrence, and the postoperative pulmonary function was well preserved. The outcomes of limited resection for small-sized lung cancer with GGOs that met the criteria of this study were satisfactory.

Entities:  

Mesh:

Year:  2018        PMID: 29236995     DOI: 10.1093/ejcts/ezx418

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  20 in total

1.  Strategy of intentional limited resection for lung adenocarcinoma in situ.

Authors:  Terumoto Koike; Teruaki Koike; Masaya Nakamura; Yuki Shimizu; Tatsuya Goto; Seijiro Sato; Masanori Tsuchida
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Preoperative 3-dimensional computed tomography lung simulation before video-assisted thoracoscopic anatomic segmentectomy for ground glass opacity in lung.

Authors:  Liang Xue; Hong Fan; Woda Shi; Di Ge; Yi Zhang; Qun Wang; Yunfeng Yuan
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

3.  3D Specimen Mapping Expedites Frozen Section Diagnosis of Nonpalpable Ground Glass Opacities.

Authors:  Gregory T Kennedy; Feredun S Azari; Elizabeth Bernstein; Charuhas Desphande; Azra Din; Isvita Marfatia; John C Kucharczuk; Edward J Delikatny; Philip S Low; Sunil Singhal
Journal:  Ann Thorac Surg       Date:  2021-11-10       Impact factor: 5.102

4.  Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.

Authors:  Masato Aragaki; Yasuhiro Hida; Tatsuya Kato; Aki Fujiwara-Kuroda; Kichizo Kaga; Satoru Wakasa
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-05       Impact factor: 4.553

5.  Surgical management of lung cancer with multiple lesions: implication of the new recommendations of the 8th edition of the TNM classification for lung cancer.

Authors:  David A Waller
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Determination of the intersegmental plane using the slip-knot method.

Authors:  Makoto Endoh; Hiroyuki Oizumi; Hirohisa Kato; Jun Suzuki; Hikaru Watarai; Akira Hamada; Katsuyuki Suzuki; Kenta Nakahashi; Mitsuaki Sadahiro
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

7.  Epidermal growth factor receptor mutation accelerates radiographic progression in lung adenocarcinoma presented as a solitary ground-glass opacity.

Authors:  Qijue Lu; Ye Ma; Zhao An; Tiejun Zhao; Zhiyun Xu; Hezhong Chen
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

8.  Anatomical segmentectomy versus pulmonary lobectomy for stage I non-small-cell lung cancer: patients selection and outcomes from the European Society of Thoracic Surgeons database analysis.

Authors:  Davide Tosi; Mario Nosotti; Gianluca Bonitta; Paolo Mendogni; Luca Bertolaccini; Lorenzo Spaggiari; Alex Brunelli; Enrico Ruffini; Pierre Emmanuel Falcoz
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-04-19

9.  Comparison of Lobectomy and Sublobar Resection for Stage IA Elderly NSCLC Patients (≥70 Years): A Population-Based Propensity Score Matching's Study.

Authors:  Bo Zhang; Renwang Liu; Dian Ren; Xiongfei Li; Yanye Wang; Huandong Huo; Shuai Zhu; Jun Chen; Zuoqing Song; Song Xu
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

10.  Surgical choice for patients with stage I non-small-cell lung cancer ≤2 cm: an analysis from surveillance, epidemiology, and end results database.

Authors:  Liang Wu; Weigang Zhao; Tangbing Chen; Yi Yang
Journal:  J Cardiothorac Surg       Date:  2021-07-07       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.